Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 134

1.

HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell-Vaccine Induced T-Cell Responses.

Andrés C, Plana M, Guardo AC, Alvarez-Fernández C, Climent N, Gallart T, León A, Clotet B, Autran B, Chomont N, Gatell JM, Sánchez-Palomino S, García F; for DCV2/MANON07-ORVACS study group.

J Virol. 2015 Jun 24. pii: JVI.01062-15. [Epub ahead of print]

PMID:
26109727
2.

Structured observations reveal slow HIV-1 CTL escape.

Roberts HE, Hurst J, Robinson N, Brown H, Flanagan P, Vass L, Fidler S, Weber J, Babiker A, Phillips RE, McLean AR, Frater J; SPARTAC trial investigators.

PLoS Genet. 2015 Feb 2;11(2):e1004914. doi: 10.1371/journal.pgen.1004914. eCollection 2015 Feb.

3.

Loading dendritic cells with PLA-p24 nanoparticles or MVA expressing HIV genes induces HIV-1-specific T cell responses.

Climent N, Munier S, Piqué N, García F, Pavot V, Primard C, Casanova V, Gatell JM, Verrier B, Gallart T.

Vaccine. 2014 Oct 29;32(47):6266-76. doi: 10.1016/j.vaccine.2014.09.010. Epub 2014 Sep 19.

PMID:
25240755
4.

HIV-1 DNA predicts disease progression and post-treatment virological control.

Williams JP, Hurst J, Stöhr W, Robinson N, Brown H, Fisher M, Kinloch S, Cooper D, Schechter M, Tambussi G, Fidler S, Carrington M, Babiker A, Weber J, Koelsch KK, Kelleher AD, Phillips RE, Frater J; SPARTACTrial Investigators.

Elife. 2014 Sep 12;3:e03821. doi: 10.7554/eLife.03821.

5.

Effects of different antigenic stimuli on thymic function and interleukin-7/CD127 system in patients with chronic HIV infection.

Castro P, Torres B, López A, González R, Vilella A, Nicolas JM, Gallart T, Pumarola T, Sánchez M, Leal M, Vallejo A, Bayas JM, Gatell JM, Plana M, García F.

J Acquir Immune Defic Syndr. 2014 Aug 15;66(5):466-72. doi: 10.1097/QAI.0000000000000207.

PMID:
24820104
6.

HIV-1-specific CD4(+) responses in primary HIV-1 infection predict disease progression.

Frater J, Ewings F, Hurst J, Brown H, Robinson N, Fidler S, Babiker A, Weber J, Porter K, Phillips RE; SPARTAC Trial Investigators.

AIDS. 2014 Mar 13;28(5):699-708. doi: 10.1097/QAD.0000000000000130.

PMID:
24549145
7.

Effect of maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals.

Kawana-Tachikawa A, Llibre JM, Bravo I, Escrig R, Mothe B, Puig J, Puertas MC, Martinez-Picado J, Blanco J, Manzardo C, Miro JM, Iwamoto A, Pozniak AL, Gatell JM, Clotet B, Brander C; MARAVIBOOST Investigators.

PLoS One. 2014 Jan 27;9(1):e87334. doi: 10.1371/journal.pone.0087334. eCollection 2014.

8.

Interleukin-6 and D-dimer levels at seroconversion as predictors of HIV-1 disease progression.

Hamlyn E, Fidler S, Stöhr W, Cooper DA, Tambussi G, Schechter M, Miro JM, Mcclure M, Weber J, Babiker A, Porter K; SPARTAC Trial Investigators.

AIDS. 2014 Mar 27;28(6):869-74. doi: 10.1097/QAD.0000000000000155.

PMID:
24300544
9.

Dendritic cell based vaccines for HIV infection: the way ahead.

García F, Plana M, Climent N, León A, Gatell JM, Gallart T.

Hum Vaccin Immunother. 2013 Nov;9(11):2445-52. Epub 2013 Aug 2. Review.

10.

Restriction of V3 region sequence divergence in the HIV-1 envelope gene during antiretroviral treatment in a cohort of recent seroconverters.

Gall A, Kaye S, Hué S, Bonsall D, Rance R, Baillie GJ, Fidler SJ, Weber JN, McClure MO, Kellam P; SPARTAC Trial Investigators.

Retrovirology. 2013 Jan 18;10:8. doi: 10.1186/1742-4690-10-8.

11.

Short-course antiretroviral therapy in primary HIV infection.

SPARTAC Trial Investigators, Fidler S, Porter K, Ewings F, Frater J, Ramjee G, Cooper D, Rees H, Fisher M, Schechter M, Kaleebu P, Tambussi G, Kinloch S, Miro JM, Kelleher A, McClure M, Kaye S, Gabriel M, Phillips R, Weber J, Babiker A.

N Engl J Med. 2013 Jan 17;368(3):207-17. doi: 10.1056/NEJMoa1110039.

12.

A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication.

García F, Climent N, Guardo AC, Gil C, León A, Autran B, Lifson JD, Martínez-Picado J, Dalmau J, Clotet B, Gatell JM, Plana M, Gallart T; DCV2/MANON07-ORVACS Study Group.

Sci Transl Med. 2013 Jan 2;5(166):166ra2. doi: 10.1126/scitranslmed.3004682.

13.

Adenosine deaminase enhances the immunogenicity of human dendritic cells from healthy and HIV-infected individuals.

Casanova V, Naval-Macabuhay I, Massanella M, Rodríguez-García M, Blanco J, Gatell JM, García F, Gallart T, Lluis C, Mallol J, Franco R, Climent N, McCormick PJ.

PLoS One. 2012;7(12):e51287. doi: 10.1371/journal.pone.0051287. Epub 2012 Dec 11.

14.

Influence of episodes of intermittent viremia ("blips") on immune responses and viral load rebound in successfully treated HIV-infected patients.

Castro P, Plana M, González R, López A, Vilella A, Nicolas JM, Gallart T, Pumarola T, Bayas JM, Gatell JM, García F.

AIDS Res Hum Retroviruses. 2013 Jan;29(1):68-76. doi: 10.1089/AID.2012.0145. Epub 2012 Dec 16.

15.

Longitudinal analysis of an HLA-B*51-restricted epitope in integrase reveals immune escape in early HIV-1 infection.

Yager N, Robinson N, Brown H, Flanagan P, Frater J, Fidler S, Weber J, Phillips R; SPARTAC Trial Investigators.

AIDS. 2013 Jan 28;27(3):313-23. doi: 10.1097/QAD.0b013e32835b8cf5.

PMID:
23095315
16.

Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection.

Hamlyn E, Ewings FM, Porter K, Cooper DA, Tambussi G, Schechter M, Pedersen C, Okulicz JF, McClure M, Babiker A, Weber J, Fidler S; INSIGHT SMART and SPARTAC Investigators.

PLoS One. 2012;7(8):e43754. Epub 2012 Aug 31.

17.

Therapeutic vaccines against HIV infection.

García F, León A, Gatell JM, Plana M, Gallart T.

Hum Vaccin Immunother. 2012 May;8(5):569-81. doi: 10.4161/hv.19555. Epub 2012 May 1. Review.

PMID:
22634436
18.

Increased levels of CD4 T-cell activation in individuals with CXCR4 using viruses in primary HIV-1 infection.

Hamlyn E, Hickling S, Porter K, Frater J, Phillips R, Robinson M, Mackie NE, Kaye S, McClure M, Fidler S; SPARTAC Investigators.

AIDS. 2012 Apr 24;26(7):887-90. doi: 10.1097/QAD.0b013e328351e721.

PMID:
22313951
19.

Effects on innate immunity of a therapeutic dendritic cell-based vaccine for HIV-1 infection.

Peña J, Frías M, Castro-Orgaz L, González R, García F, Gallart T, Gatell JM, Plana M; Dc2-Manon07 Vaccine Research Group.

Viral Immunol. 2012 Feb;25(1):37-44. doi: 10.1089/vim.2011.0044. Epub 2012 Jan 10.

20.

[Clinical management of acute and chronic human immunodeficiency virus infection before starting antiretroviral treatment].

Miró JM, Manzardo C, Zamora L, Pumarola T, Herreras Z, Gallart T, Gatell JM.

Enferm Infecc Microbiol Clin. 2011 Dec;29(10):759-72. doi: 10.1016/j.eimc.2011.10.009. Epub 2011 Nov 10. Review. Spanish.

PMID:
22078726
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk